Budesonide in the Management of Patients with Crohn’s Disease
Modern medical therapy is increasingly based on evidence. The evidence presented here is that budesonide (Entocort, Astra Pharma) 9 mg/day is superior to placebo and equivalent to systemically active glucocorticoster...
Saved in:
Main Authors: | ABR Thomson, Daniel Sadowski, Robert Jenkins, Gary Wild |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
1997-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/1997/271653 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Esophageal Crohn's Disease Treated “Topically” with Swallowed Aerosolized Budesonide
by: Petros Zezos, et al.
Published: (2010-01-01) -
A Gastroenterologist’s Perspective of The Medical Management of Patients with Crohn’s Disease and Ulcerative Colitis
by: ABR Thomson
Published: (1996-01-01) -
Disorders of Mineral and Bone Metabolism in Patients with Crohn's Disease
by: C. Von Westarp, et al.
Published: (1987-01-01) -
Small Bowel Review - Part II
by: ABR Thomson, et al.
Published: (1997-01-01) -
Small Bowel Review - Part I
by: ABR Thomson, et al.
Published: (1997-01-01)